ACC.26 - This Market Watch episode from ACC.26 offers an unusually clear window into how one major device company is thinking about the future of interventional AF, from trial design to day-to-day practice. In an independent, editorially led discussion, host Brad Wilson speaks with Dr Brad Sutton, Chief Medical Officer for Atrial Fibrillation Solutions at Boston Scientific, about what CHAMPION-AF and the broader LAAC data set mean for operators at the table today.  

The interview moves beyond headline results to examine how WATCHMAN, FARAPULSE pulsed field ablation, and emerging concomitant strategies are influencing referral patterns, patient selection, and program development in real-world settings. The focus is squarely on evidence, workflow, and health-system realities rather than promotion, offering viewers a practical, forward-looking take on where interventional AF therapy is heading and how Boston Scientific’s strategy may shape that landscape.

For more expert insights and late-breaking science from ACC 2026, visit the Late-breaking Science Video Collection.